Johan Burisch

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3981752/publications.pdf

Version: 2024-02-01

216 papers 11,932 citations

50276 46 h-index 30087 103 g-index

220 all docs 220 docs citations

times ranked

220

10239 citing authors

#	Article	IF	CITATIONS
1	The Impact of Periodontitis on Inflammatory Bowel Disease Activity. Inflammatory Bowel Diseases, 2023, 29, 396-404.	1.9	12
2	Histological Inflammation in the Endoscopically Uninflamed Mucosa is Associated With Worse Outcomes in Limited Ulcerative Colitis. Inflammatory Bowel Diseases, 2022, 28, 350-357.	1.9	4
3	COVIDâ€19–related personal product shortages are associated with psychological distress in people living with gastrointestinal disorders: A crossâ€sectional survey. Neurogastroenterology and Motility, 2022, 34, e14198.	3.0	9
4	Microscopic Colitis in Denmark: Regional Variations in Risk Factors and Frequency of Endoscopic Procedures. Journal of Crohn's and Colitis, 2022, 16, 49-56.	1.3	6
5	ECCO Topical Review on Clinicopathological Spectrum and Differential Diagnosis of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2022, 16, 343-368.	1.3	17
6	Exploring the Relationship Between Self-Isolation and Distress Among People with Gastrointestinal Disorders During the COVID-19 Pandemic. Journal of Clinical Psychology in Medical Settings, 2022, 29, 654-665.	1.4	6
7	The clinical course of Crohn's disease in a Danish populationâ€based inception cohort with more than 50Âyears of followâ€up, 1962â€2017. Alimentary Pharmacology and Therapeutics, 2022, 55, 73-82.	3.7	11
8	Extending the Common Sense Model to Explore the Impact of the Fear of COVID-19 on Quality of Life in an International Inflammatory Bowel Disease Cohort. Journal of Clinical Psychology in Medical Settings, 2022, 29, 678-688.	1.4	8
9	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Surgical Treatment. Journal of Crohn's and Colitis, 2022, 16, 179-189.	1.3	120
10	ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment. Journal of Crohn's and Colitis, 2022, 16, 2-17.	1.3	288
11	Surgery, cancer and mortality among patients with ulcerative colitis diagnosed 1962â€1987 and followed until 2017 in a Danish populationâ€based inception cohort. Alimentary Pharmacology and Therapeutics, 2022, 55, 339-349.	3.7	12
12	Outcomes and Long-Term Effects of COVID-19 in Patients with Inflammatory Bowel Diseases – A Danish Prospective Population-Based Cohort Study with Individual-Level Data. Journal of Crohn's and Colitis, 2022, 16, 757-767.	1.3	13
13	P293 Insights from patients with Ulcerative Colitis on disease burden: Findings from a real-world survey in Europe. Journal of Crohn's and Colitis, 2022, 16, i324-i325.	1.3	1
14	P649 The impact of COVID-19 on quality of life among patients with inflammatory bowel diseases – A Danish prospective population-based cohort study. Journal of Crohn's and Colitis, 2022, 16, i562-i565.	1.3	1
15	P238 Symptom burden and indolent disease in newly diagnosed patients with ulcerative colitis and Crohnမs disease - a Copenhagen IBD Inception Cohort Study. Journal of Crohn's and Colitis, 2022, 16, i285-i287.	1.3	0
16	DOP03 The use and efficacy of biological therapies 2010–2020 for Inflammatory Bowel Disease in a Danish tertiary centre. Journal of Crohn's and Colitis, 2022, 16, i053-i054.	1.3	0
17	P287 The knowledge and skills needed to perform intestinal ultrasound – An international Delphi consensus survey. Journal of Crohn's and Colitis, 2022, 16, i319-i320.	1.3	1
18	P641 Implementation and short-term adverse events of anti-SARS-CoV-2 vaccines in Inflammatory Bowel Disease patients: an international web-based survey. Journal of Crohn's and Colitis, 2022, 16, i558-i558.	1.3	0

#	Article	IF	CITATIONS
19	DOP10 Intestinal Ultrasound at IBD diagnosis predicts major disease events – A Copenhagen IBD cohort study. Journal of Crohn's and Colitis, 2022, 16, i059-i060.	1.3	О
20	Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. Gastroenterology, 2022, 162, 1476-1492.	1.3	19
21	P258 Impact of inflammatory bowel diseases on the phenotype and severity of primary sclerosing cholangitis - a systematic review with meta-analysis. Journal of Crohn's and Colitis, 2022, 16, i299-i300.	1.3	0
22	DOP22 Clinical, biochemical and endoscopic disease activity of Inflammatory Bowel Diseases are not associated with the severity or long-term outcomes of COVID-19 – A Danish prospective population-based cohort study. Journal of Crohn's and Colitis, 2022, 16, i071-i072.	1.3	0
23	P530 Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis. Journal of Crohn's and Colitis, 2022, 16, i483-i484.	1.3	0
24	DOP23 Long-term health consequences of COVID-19 in patients with Inflammatory Bowel Diseases – A Danish prospective population-based cohort study. Journal of Crohn's and Colitis, 2022, 16, i072-i074.	1.3	0
25	P656 The impact of periodontitis on IBD disease activity. Journal of Crohn's and Colitis, 2022, 16, i568-i569.	1.3	0
26	P686 Outcomes of COVID-19 among patients with inflammatory bowel diseases and the influence of IBD-related medications– A Danish prospective population-based cohort study. Journal of Crohn's and Colitis, 2022, 16, i587-i589.	1.3	0
27	Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey. Journal of Crohn's and Colitis, 2022, 16, 1070-1078.	1.3	9
28	Similar Gut Bacterial Composition Between Patients With Ulcerative Colitis and Healthy Controls in a High Incidence Population: A Cross-sectional Study of the Faroe Islands IBD Cohort. Inflammatory Bowel Diseases, 2022, 28, 1081-1089.	1.9	5
29	Inflammatory Bowel Diseases Affect the Phenotype and Disease Course of Coexisting Immune-Mediated Inflammatory Diseases: A Systematic Review With Meta-Analysis. Inflammatory Bowel Diseases, 2022, , .	1.9	5
30	Association Between the Clinical, Biochemical, and Endoscopic Activity of Inflammatory Bowel Diseases and Severity and Long-term Outcomes of Coronavirus Disease 2019—A Population-based Study. Inflammatory Bowel Diseases, 2022, , .	1.9	1
31	Validation of the Endoscopic Part of the Spigelman Classification for Evaluating Duodenal Adenomatosis in Familial Adenomatous Polyposis: A Prospective Study of Interrater and Intrarater Reliability. American Journal of Gastroenterology, 2022, 117, 343-345.	0.4	3
32	Trends in the use of biologicals and their treatment outcomes among patients with inflammatory bowel diseases $\hat{a} \in a$ Danish nationwide cohort study. Alimentary Pharmacology and Therapeutics, 2022, 55, 541-557.	3.7	28
33	Editorial: delving into the natural history of Crohn's disease and the impact of medical therapy—authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 110-111.	3.7	0
34	Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis. Digestive and Liver Disease, 2022, 54, 1168-1178.	0.9	17
35	A Narrative Systematic Review and Categorisation of Outcomes in Inflammatory Bowel Disease to Inform a Core Outcome Set for Real-world Evidence. Journal of Crohn's and Colitis, 2022, 16, 1511-1522.	1.3	6
36	Letter: the clinical course of Crohn's diseaseâ€"the Sicilian experience. Authors' reply. Alimentary Pharmacology and Therapeutics, 2022, 55, 1239-1240.	3.7	0

#	Article	IF	CITATIONS
37	The knowledge and skills needed to perform intestinal ultrasound for inflammatory bowel diseases—an international Delphi consensus survey. Alimentary Pharmacology and Therapeutics, 2022, 56, 263-270.	3.7	7
38	Influence of Genetics, Immunity and the Microbiome on the Prognosis of Inflammatory Bowel Disease (IBD Prognosis Study): the protocol for a Copenhagen IBD Inception Cohort Study. BMJ Open, 2022, 12, e055779.	1.9	3
39	Outcomes of COVID-19 among Patients with Chronic Liver Disease: A Danish Prospective, Population-Based Cohort Study. GastroHep, 2022, 2022, 1-10.	0.6	1
40	Psychiatric Disorders in Adult and Paediatric Patients With Inflammatory Bowel Diseases – A Systematic Review and Meta-Analysis. Journal of Crohn's and Colitis, 2022, 16, 1933-1945.	1.3	11
41	The Incidence and Disease Course of Perianal Crohn's Disease: A Danish Nationwide Cohort Study, 1997–2015. Journal of Crohn's and Colitis, 2021, 15, 5-13.	1.3	30
42	The Risk of Extraintestinal Cancer in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Cohort Studies. Clinical Gastroenterology and Hepatology, 2021, 19, 1117-1138.e19.	4.4	44
43	Systematic Review with Meta-analysis: The Impact of Co-occurring Immune-mediated Inflammatory Diseases on the Disease Course of Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2021, 27, 927-939.	1.9	16
44	Prevalence and Outcomes of COVID-19 Among Patients With Inflammatory Bowel Disease—A Danish Prospective Population-based Cohort Study. Journal of Crohn's and Colitis, 2021, 15, 540-550.	1.3	63
45	Disease Activity Patterns, Mortality, and Colorectal Cancer Risk in Microscopic Colitis: A Danish Nationwide Cohort Study, 2001 to 2016. Journal of Crohn's and Colitis, 2021, 15, 594-602.	1.3	11
46	Efficacy of ustekinumab for active perianal fistulizing Crohn's disease: a systematic review and meta-analysis of the current literature. Scandinavian Journal of Gastroenterology, 2021, 56, 53-58.	1.5	36
47	Efficacy of Ustekinumab for Active Perianal Fistulizing Crohn Disease: A Double-Center Cohort Study. Inflammatory Bowel Diseases, 2021, 27, e37-e38.	1.9	10
48	Systematic review and meta-analysis: the impact of co-occurring immune-mediated inflammatory diseases on the disease localization and behavior of Crohn's disease. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110048.	3.2	2
49	A Danish population-based case series of patients with liver cirrhosis and coronavirus disease 2019. Scandinavian Journal of Gastroenterology, 2021, 56, 453-457.	1.5	3
50	The Burden of Inflammatory Bowel Disease in Europe in 2020. Journal of Crohn's and Colitis, 2021, 15, 1573-1587.	1.3	160
51	Costs of electronic health vs. standard care management of inflammatory bowel disease across three years of follow-up–a Danish register-based study. Scandinavian Journal of Gastroenterology, 2021, 56, 520-529.	1.5	4
52	Authors' Response: Interpretations of Trends in Incidence of Microscopic Colitis. Journal of Crohn's and Colitis, 2021, 15, 344-344.	1.3	0
53	Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?. Gut, 2021, 70, 2020-2022.	12.1	13
54	Patient Reported Outcomes in Chronic Inflammatory Diseases: Current State, Limitations and Perspectives. Frontiers in Immunology, 2021, 12, 614653.	4.8	7

#	Article	IF	CITATIONS
55	Coronavirus disease 2019, immune-mediated inflammatory diseases and immunosuppressive therapies – A Danish population-based cohort study. Journal of Autoimmunity, 2021, 118, 102613.	6.5	41
56	OPO7 Artificial intelligence surpasses gastrointestinal experts in the classification of endoscopic severity among Ulcerative Colitis. Journal of Crohn's and Colitis, 2021, 15, S007-S007.	1.3	2
57	P162 Microscopic inflammation in limited Ulcerative Colitis at diagnosis: can a single histological feature predict prognosis?. Journal of Crohn's and Colitis, 2021, 15, S240-S240.	1.3	0
58	P421 Treatment optimization with vedolizumab in treatment-refractory patients with ulcerative colitis and Crohn's disease – a real-world two-center cohort study. Journal of Crohn's and Colitis, 2021, 15, S425-S426.	1.3	0
59	DOP43 Impact of Inflammatory Bowel Diseases on the phenotype and severity of psoriasis and spondyloarthropathies. Journal of Crohn's and Colitis, 2021, 15, S081-S081.	1.3	O
60	P102 Outcomes of coronavirus disease 2019 among patients with inflammatory bowel diseases and the influence of IBD-related medications– A Danish prospective population-based cohort study. Journal of Crohn's and Colitis, 2021, 15, S197-S197.	1.3	0
61	P603 Patient characteristics and adverse effects in biologic treatment of Crohn's Disease and Ulcerative Colitis: A nationwide Danish cohort study years 2015–2018. Journal of Crohn's and Colitis, 2021, 15, S548-S549.	1.3	0
62	P274 Drug utilization of biologic therapy in Crohnâ∈™s disease and ulcerative colitis: A population based Danish cohort study 2015-2018. Journal of Crohn's and Colitis, 2021, 15, S306-S307.	1.3	0
63	P610 Fear of COVID-19 among persons with Inflammatory Bowel Disease according to employment status, educational background and residential setting, as compared to persons with other gastrointestinal conditions. Journal of Crohn's and Colitis, 2021, 15, S554-S556.	1.3	0
64	DOP78 The differential diagnosis and clinicopathological spectrum of Inflammatory Bowel Disease: An interesting and informative ECCO topical review. Journal of Crohn's and Colitis, 2021, 15, S110-S111.	1.3	0
65	Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study. Journal of Clinical Medicine, 2021, 10, 2914.	2.4	8
66	Short and long-term effectiveness and safety of vedolizumab in treatment-refractory patients with ulcerative colitis and Crohnâ \in Ms disease â \in a real-world two-center cohort study. European Journal of Gastroenterology and Hepatology, 2021, 33, e709-e718.	1.6	11
67	ECCO Topical Review: Refractory Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2021, 15, 1605-1620.	1.3	16
68	Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scandinavian Journal of Gastroenterology, 2021, 56, 1040-1048.	1.5	12
69	Artificial intelligence assisted assessment of endoscopic disease activity in inflammatory bowel disease. Artificial Intelligence in Gastrointestinal Endoscopy, 2021, 2, 95-102.	0.3	1
70	The impact of the coronavirus (COVID-19) pandemic on individuals with gastrointestinal disorders: A protocol of an international collaborative study. Journal of Psychosomatic Research, 2021, 148, 110561.	2.6	7
71	Validation and Update of the Lémann Index to Measure Cumulative Structural Bowel Damage in Crohn's Disease. Gastroenterology, 2021, 161, 853-864.e13.	1.3	28
72	Occurrence of Colorectal Cancer and the Influence of Medical Treatment in Patients With Inflammatory Bowel Disease: A Danish Nationwide Cohort Study, 1997 to 2015. Inflammatory Bowel Diseases, 2021, 27, 1795-1803.	1.9	11

#	Article	IF	CITATIONS
73	Validation of claims-based indicators used to identify flare-ups in inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110048.	3.2	4
74	Authors' Reply to: â€~COVID-19 in the IBD Population: The Need for Correct Nomenclature'. Journal of Crohn's and Colitis, 2021, 15, 1080-1080.	1.3	0
7 5	Assessing aCCess to Investigations in Inflammatory Bowel Disease (ACCID). European Journal of Gastroenterology and Hepatology, 2021, Publish Ahead of Print, e837-e842.	1.6	1
76	Long-Term Effects of a Web-Based Low-FODMAP Diet Versus Probiotic Treatment for Irritable Bowel Syndrome, Including Shotgun Analyses of Microbiota: Randomized, Double-Crossover Clinical Trial. Journal of Medical Internet Research, 2021, 23, e30291.	4.3	15
77	The LUCID study: living with ulcerative colitis; identifying the socioeconomic burden in Europe. BMC Gastroenterology, 2021, 21, 456.	2.0	8
78	Direct and Indirect Costs of Inflammatory Bowel Disease: Ten Years of Follow-up in a Danish Population-based Inception Cohort. Journal of Crohn's and Colitis, 2020, 14, 53-63.	1.3	39
79	Viewpoint: Inflammatory Bowel Diseases Among Immigrants From Low- to High-Incidence Countries: Opportunities and Considerations. Journal of Crohn's and Colitis, 2020, 14, 267-273.	1.3	24
80	Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Diseaseâ€"A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis, 2020, 14, 351-360.	1.3	58
81	Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes. Clinical Gastroenterology and Hepatology, 2020, 18, 1152-1160.e1.	4.4	19
82	ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. Journal of Crohn's and Colitis, 2020, 14, 4-22.	1.3	741
83	The epidemiology of inflammatory bowel disease: East meets west. Journal of Gastroenterology and Hepatology (Australia), 2020, 35, 380-389.	2.8	334
84	ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. Journal of Crohn's and Colitis, 2020, 14, 155-168.	1.3	478
85	Outcome of concomitant treatment with thiopurines and allopurinol in patients with inflammatory bowel disease: A nationwide Danish cohort study. United European Gastroenterology Journal, 2020, 8, 68-76.	3.8	14
86	eHealth: Disease activity measures are related to the faecal gut microbiota in adult patients with ulcerative colitis. Scandinavian Journal of Gastroenterology, 2020, 55, 1291-1300.	1.5	5
87	The Sooner the Better? Cost-effectiveness of Early Biological Therapy in Patients With Crohn's Disease. Journal of Crohn's and Colitis, 2020, 14, 573-574.	1.3	1
88	Predictors of response and disease course in patients with inflammatory bowel disease treated with biological therapyâ€"the Danish IBD Biobank Project: protocol for a multicentre prospective cohort study. BMJ Open, 2020, 10, e035756.	1.9	8
89	The prevention and management of Crohn's disease postoperative recurrence: results from the Y-ECCO/ClinCom 2019 Survey. European Journal of Gastroenterology and Hepatology, 2020, 32, 1062-1066.	1.6	8
90	The use of 5â€aminosalicylate for patients with Crohn's disease in a prospective European inception cohort with 5 years followâ€up – an Epiâ€ŀBD study. United European Gastroenterology Journal, 2020, 8, 949-960.	3.8	17

#	Article	IF	CITATIONS
91	Validation of ulcerative colitis and Crohn's disease and their phenotypes in the Danish National Patient Registry using a population-based cohort. Scandinavian Journal of Gastroenterology, 2020, 55, 1171-1175.	1.5	27
92	Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. PLoS ONE, 2020, 15, e0233781.	2.5	32
93	Cancer Risk in Pediatric-Onset Inflammatory Bowel Disease: A Population-Based Danish Cohort Study. Gastroenterology, 2020, 159, 1609-1611.	1.3	9
94	Incidence and Prevalence of Microscopic Colitis Between 2001 and 2016: A Danish Nationwide Cohort Study. Journal of Crohn's and Colitis, 2020, 14, 1717-1723.	1.3	30
95	OP12 The incidence and disease course of perianal Crohn's disease: A Danish nationwide cohort study. Journal of Crohn's and Colitis, 2020, 14, S012-S012.	1.3	2
96	P261 Systematic review with meta-analysis: The impact of concomitant immune-mediated diseases on the disease course of inflammatory bowel disease. Journal of Crohn's and Colitis, 2020, 14, S280-S281.	1.3	0
97	Quality of Care Standards in Inflammatory Bowel Diseases: a European Crohn's and Colitis Organisation [ECCO] Position Paper. Journal of Crohn's and Colitis, 2020, 14, 1037-1048.	1.3	55
98	Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study. The Lancet Gastroenterology and Hepatology, 2020, 5, 454-464.	8.1	76
99	Incidence, Risk Factors and Evaluation of Osteoporosis in Patients With Inflammatory Bowel Disease: A Danish Population-Based Inception Cohort With 10 Years of Follow-Up. Journal of Crohn's and Colitis, 2020, 14, 904-914.	1.3	15
100	DOP43 The risk of extra-intestinal cancer in inflammatory bowel disease (IBD): A systematic review and meta-analysis of population-based cohort studies. Journal of Crohn's and Colitis, 2020, 14, S080-S081.	1.3	0
101	Current challenges and future needs of clinical and endoscopic training in gastroenterology: a European survey. Endoscopy International Open, 2020, 08, E525-E533.	1.8	13
102	OP35 Treatment outcomes of inflammatory bowel disease in the biological eraâ€"a nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study. Journal of Crohn's and Colitis, 2020, 14, S036-S037.	1.3	2
103	Systematic review of the prevalence and development of osteoporosis or low bone mineral density and its risk factors in patients with inflammatory bowel disease. World Journal of Gastroenterology, 2020, 26, 5362-5374.	3.3	17
104	Inflammatory Bowel Disease and Parkinson's Disease: A Nationwide Swedish Cohort Study. Inflammatory Bowel Diseases, 2019, 25, 111-123.	1.9	117
105	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications. Journal of Crohn's and Colitis, 2019, 13, 144-164K.	1.3	958
106	ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects. Journal of Crohn's and Colitis, 2019, 13, 273-284.	1.3	250
107	Association between inflammatory bowel disease and Parkinson's disease: seek and you shall find?. Gut, 2019, 68, 175-176.	12.1	16
108	Healthâ€related quality of life in inflammatory bowel disease in a Danish populationâ€based inception cohort. United European Gastroenterology Journal, 2019, 7, 942-954.	3.8	17

#	Article	IF	CITATIONS
109	Changing epidemiology of immune-mediated inflammatory diseases in immigrants: A systematic review of population-based studies. Journal of Autoimmunity, 2019, 105, 102303.	6.5	31
110	Dietary risk factors for inflammatory bowel diseases in a highâ€risk population: Results from the Faroese IBD study. United European Gastroenterology Journal, 2019, 7, 924-932.	3.8	15
111	Inflammatory Bowel Disease and Parkinson's Disease: A Reply to Letter to the Editor of Shih-Wei Lai. Inflammatory Bowel Diseases, 2019, 25, e127-e127.	1.9	0
112	OP15 Cost analysis in a prospective European population-based inception cohort: is there a cost-saving effect of biological therapy?. Journal of Crohn's and Colitis, 2019, 13, S009-S010.	1.3	1
113	DOP76 Prevalence and healthcare costs of perianal fistulas in Crohn's disease in a nationwide cohort. Journal of Crohn's and Colitis, 2019, 13, S076-S076.	1.3	1
114	DOP82 Direct and indirect costs of inflammatory bowel disease in the biological era; 10 years of follow-up in a Danish population-based inception cohort. Journal of Crohn's and Colitis, 2019, 13, S079-S080.	1.3	1
115	DOP86 Risk for development of inflammatory bowel disease under inhibition of interleukin 17 in psoriasis, psoriatic arthritis, ankylosing spondylitis, and rheumatoid arthritis: a review and meta-analysis. Journal of Crohn's and Colitis, 2019, 13, S082-S082.	1.3	0
116	DOP88 Thiopurine and allopurinol combination therapy and the risk of adverse outcomes and step-up medical therapy in inflammatory bowel disease patients: a nationwide Danish cohort study. Journal of Crohn's and Colitis, 2019, 13, S083-S083.	1.3	0
117	Incidence of Immune-Mediated Inflammatory Diseases Among Patients With Inflammatory Bowel Diseases in Denmark. Clinical Gastroenterology and Hepatology, 2019, 17, 2704-2712.e3.	4.4	54
118	Impact of Genes and the Environment on the Pathogenesis and Disease Course of Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2019, 64, 1759-1769.	2.3	41
119	P780 Medical treatment and surgery in patients with elderly-onset inflammatory bowel disease: 3-year follow-up of Epi-IBD 2010–2011 cohorts. Journal of Crohn's and Colitis, 2019, 13, S510-S511.	1.3	0
120	Trends in hospitalisation rates for inflammatory bowel disease in western versus newly industrialised countries: a population-based study of countries in the Organisation for Economic Co-operation and Development. The Lancet Gastroenterology and Hepatology, 2019, 4, 287-295.	8.1	44
121	P404 Stopping 5-aminosalicylates in Crohn's disease patients starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts. Journal of Crohn's and Colitis, 2019, 13, S310-S311.	1.3	0
122	P823 Study launch: Investigating genetic and environmental factors in the faroese IBD cohortâ€"the INCEPTION study. Journal of Crohn's and Colitis, 2019, 13, S534-S535.	1.3	0
123	P743 Bone mineral disease is insufficiently evaluated in patients with inflammatory bowel disease at risk of metabolic bone disease: results from a Danish population-based inception cohort study. Journal of Crohn's and Colitis, 2019, 13, S493-S494.	1.3	0
124	Polymorphisms in the <scp>NF</scp> kB, <scp>TNF</scp> â€alpha, <scp>IL</scp> â€1 beta, and <scp>IL</scp> â€1 pathways are associated with response to antiâ€ <scp>TNF</scp> therapy in Danish patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 890-903.	8 3.7	52
125	Sexâ€based differences in the incidence of inflammatory bowel diseasesâ€"pooled analysis of populationâ€based studies from the Asiaâ€Pacific region. Alimentary Pharmacology and Therapeutics, 2019, 49, 904-911.	3.7	48
126	Does Eradication of Helicobacter Pylori Cause Inflammatory Bowel Disease?. Clinical Gastroenterology and Hepatology, 2019, 17, 1940-1941.	4.4	6

#	Article	IF	CITATIONS
127	Colorectal Cancer in Individuals With Familial Adenomatous Polyposis, Based on Analysis of the Danish Polyposis Registry. Clinical Gastroenterology and Hepatology, 2019, 17, 2294-2300.e1.	4.4	22
128	744 The Impact of Ulcerative Colitis on Quality of Life and Productivity Across Europe: A Burden of Illness Study. American Journal of Gastroenterology, 2019, 114, S436-S437.	0.4	0
129	A 10-Year Follow-up Study of the Natural History of Perianal Crohn's Disease in a Danish Population-Based Inception Cohort. Inflammatory Bowel Diseases, 2019, 25, 1227-1236.	1.9	44
130	Disease course of inflammatory bowel disease unclassified in a European populationâ€based inception cohort: An Epiâ€IBD study. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 996-1003.	2.8	19
131	The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. Journal of Crohn's and Colitis, 2019, 13, 541-554.	1.3	112
132	Incidence and Risk of Inflammatory Bowel Disease in Patients with Psoriasisâ€"A Nationwide 20-Year Cohort Study. Journal of Investigative Dermatology, 2019, 139, 316-323.	0.7	35
133	Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort—An Epi-IBD Study. Journal of Crohn's and Colitis, 2019, 13, 198-208.	1.3	100
134	Natural disease course of Crohn's disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut, 2019, 68, 423-433.	12.1	176
135	Ethnic differences in inflammatory bowel disease: Results from the United Kingdom inception epidemiology study. World Journal of Gastroenterology, 2019, 25, 6145-6157.	3.3	24
136	Individualized home-monitoring of disease activity in adult patients with inflammatory bowel disease can be recommended in clinical practice: A randomized-clinical trial. World Journal of Gastroenterology, 2019, 25, 6158-6171.	3.3	15
137	Exposome and Diet. , 2019, , 281-291.		0
138	COLORECTAL CANCER IN FAMILIAL ADENOMATOUS POLYPOSIS: RESULTS FROM THE DANISH POLYPOSIS REGISTRY. Endoscopy, 2019, 51, .	1.8	0
139	743 The Socioeconomic Impact of Living With Ulcerative Colitis: A Burden of Illness Study. American Journal of Gastroenterology, 2019, 114, S436-S436.	0.4	0
140	The Importance of Detecting Irritable Bowel-like Symptoms in Inflammatory Bowel Disease Patients. Journal of Crohn's and Colitis, 2018, 12, 385-386.	1.3	4
141	Validation of the â€~United Registries for Clinical Assessment and Research' [UR-CARE], a European Online Registry for Clinical Care and Research in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 532-537.	1.3	8
142	Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy. Pharmacogenomics Journal, 2018, 18, 87-97.	2.0	42
143	Changes in Disease Behaviour and Location in Patients With Crohn's Disease After Seven Years of Follow-Up: A Danish Population-based Inception Cohort. Journal of Crohn's and Colitis, 2018, 12, 265-272.	1.3	49
144	European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal [â€~Exit Strategies'] in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 17-31.	1.3	151

#	Article	IF	Citations
145	Systematic review and metaâ€analysis: assessment of factors affecting disability in inflammatory bowel disease and the reliability of the inflammatory bowel disease disability index. Alimentary Pharmacology and Therapeutics, 2018, 47, 6-15.	3.7	44
146	Epidemiology of inflammatory bowel disease in racial and ethnic migrant groups. World Journal of Gastroenterology, 2018, 24, 424-437.	3.3	38
147	Disease activity, steroid use and extraintestinal manifestation are associated with increased disability in patients with inflammatory bowel disease using the inflammatory bowel disease disability index: a cross-sectional multicentre cohort study. European Journal of Gastroenterology and Hepatology, 2018. 30. 1130-1136.	1.6	14
148	Sex-Based Differences in Incidence of Inflammatory Bowel Diseasesâ€"Pooled Analysis of Population-Based Studies From Western Countries. Gastroenterology, 2018, 155, 1079-1089.e3.	1.3	155
149	Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study. European Journal of Gastroenterology and Hepatology, 2018, 30, 1297-1303.	1.6	27
150	Efficacy of different faecal microbiota transplantation protocols for <i>Clostridium difficile</i> infection: A systematic review and metaâ€analysis. United European Gastroenterology Journal, 2018, 6, 1232-1244.	3.8	137
151	P813 Occurrence, disease course and prognosis of perianal Crohn's disease in a Danish population-based inception cohort—a 10-year follow-up study. Journal of Crohn's and Colitis, 2018, 12, S524-S525.	1.3	2
152	IBD2020 global forum: results of an international patient survey on quality of care. Intestinal Research, 2018, 16, 537-545.	2.6	20
153	European Crohn's and Colitis Organisation Topical Review on environmental factors in IBD. Journal of Crohn's and Colitis, 2017, 11, jjw223.	1.3	27
154	The incidence of inflammatory bowel disease in Denmark 1980–2013: a nationwide cohort study. Alimentary Pharmacology and Therapeutics, 2017, 45, 961-972.	3.7	112
155	Using eHealth strategies in delivering dietary and other therapies in patients with irritable bowel syndrome and inflammatory bowel disease. Journal of Gastroenterology and Hepatology (Australia), 2017, 32, 27-31.	2.8	21
156	Inflammatory bowel diseases in Faroeseâ€born Danish residents and their offspring: further evidence of the dominant role of environmental factors in IBD development. Alimentary Pharmacology and Therapeutics, 2017, 45, 1107-1114.	3.7	25
157	Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and lleo-anal Pouch Disorders. Journal of Crohn's and Colitis, 2017, 11, 649-670.	1.3	1,324
158	Proximal Disease Extension in Patients With Limited Ulcerative Colitis: A Danish Population-based Inception Cohort. Journal of Crohn's and Colitis, 2017, 11, 1200-1204.	1.3	34
159	Defining success in treating patients with inflammatory bowel disease. Expert Review of Clinical Immunology, 2017, 13, 645-647.	3.0	3
160	Systematic review with metaâ€analysis: proximal disease extension in limited ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2017, 45, 1481-1492.	3.7	55
161	Whats â€~App-ening'. Current Opinion in Clinical Nutrition and Metabolic Care, 2017, 20, 426-431.	2.5	11
162	Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohortâ€"An ECCO-EpiCom Study. Journal of Crohn's and Colitis, 2017, 11, 1213-1222.	1.3	23

#	Article	IF	CITATIONS
163	Letter: determining the dominant role of environmental factors in <scp>UC</scp> development―Authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 78-79.	3.7	O
164	Evaluation of Quality of Life in Crohn's Disease and Ulcerative Colitis: What Is Health-Related Quality of Life?., 2017,, 279-289.		2
165	DOP001 European Crohn's and Colitis Organisation topical review on environmental factors in IBD. Journal of Crohn's and Colitis, 2017, 11, S26-S26.	1.3	27
166	How to start a Young GI Section in your country – A cookbook. United European Gastroenterology Journal, 2017, 5, 910-912.	3.8	2
167	The organisation and needs of young sections belonging to UEG National Societies: Results of a Europeâ€wide survey. United European Gastroenterology Journal, 2017, 5, 750-755.	3.8	3
168	Low-FODMAP diet reduces irritable bowel symptoms in patients with inflammatory bowel disease. World Journal of Gastroenterology, 2017, 23, 3356.	3.3	125
169	P745 Impact of migration on IBD incidence in 8 European populations: results from Epicom 2010 inception cohort study. Journal of Crohn's and Colitis, 2017, 11, S463-S463.	1.3	4
170	Assessing medication adherence in inflammatory bowel diseases. A comparison between a self-administered scale and a pharmacy refill index. Revista Espanola De Enfermedades Digestivas, 2017, 109, 539-541.	0.3	1
171	The Incidence of Inflammatory Bowel Disease in 7 Ethnically Diverse Urban Populations in England: Results From the U.K. INception CohorT Epidemiological Study (UNITE). American Journal of Gastroenterology, 2017, 112, S381.	0.4	0
172	Follow-up of patients with functional bowel symptoms treated with a low FODMAP diet. World Journal of Gastroenterology, 2016, 22, 4009.	3.3	104
173	Fecal Calprotectin Measured By Patients at Home Using Smartphonesâ€"A New Clinical Tool in Monitoring Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 336-344.	1.9	73
174	Preclinical disease and preventive strategies in IBD: perspectives, challenges and opportunities. Gut, 2016, 65, 1061-1069.	12.1	68
175	Young GI Angle: What makes for a good mentor?. United European Gastroenterology Journal, 2016, 4, 320-320.	3.8	1
176	The Faroese IBD Study: Incidence of Inflammatory Bowel Diseases Across 54 Years of Population-based Data. Journal of Crohn's and Colitis, 2016, 10, 934-942.	1.3	61
177	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 239-254.	1.3	577
178	Telemonitoring and Self-Care in Patients with IBD. , 2016, , 85-99.		2
179	Rejuvenating UEG: The Young Talent Group and the Young GI Network. United European Gastroenterology Journal, 2015, 3, 99-99.	3.8	3
180	The epidemiology of inflammatory bowel disease. Scandinavian Journal of Gastroenterology, 2015, 50, 942-951.	1.5	272

#	Article	IF	CITATIONS
181	Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort. Journal of Crohn's and Colitis, 2015, 9, 747-753.	1.3	38
182	Environment and invironment in IBDs: partners in crime. Gut, 2015, 64, 1009-1010.	12.1	7
183	Su1070 Incidence of Inflammatory Bowel Diseases in the Faroe Islands From 1960-2014: A 54-Year Overview From a Population-Based Cohort. Gastroenterology, 2015, 148, S-399.	1.3	0
184	Costs and Resource Utilization for Diagnosis and Treatment During the Initial Year in a European Inflammatory Bowel Disease Inception Cohort. Inflammatory Bowel Diseases, 2015, 21, 121-131.	1.9	47
185	Polymorphisms in the Toll-Like Receptor and the IL-23/IL-17 Pathways Were Associated with Susceptibility to Inflammatory Bowel Disease in a Danish Cohort. PLoS ONE, 2015, 10, e0145302.	2.5	47
186	Effectiveness of anti-tumour necrosis factor- \hat{l}_{\pm} therapy in Danish patients with inflammatory bowel diseases. Danish Medical Journal, 2015, 62, .	0.5	5
187	Polymorphisms in the Inflammatory Pathway Genes TLR2, TLR4, TLR9, LY96, NFKBIA, NFKB1, TNFA, TNFRSF1A, IL6R, IL10, IL23R, PTPN22, and PPARG Are Associated with Susceptibility of Inflammatory Bowel Disease in a Danish Cohort. PLoS ONE, 2014, 9, e98815.	2.5	102
188	Ehealth: Low FODMAP diet <i>vs Lactobacillus rhamnosus</i> GG in irritable bowel syndrome. World Journal of Gastroenterology, 2014, 20, 16215.	3.3	155
189	Associations between functional polymorphisms in the NFÎ $^\circ$ B signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease. Pharmacogenomics Journal, 2014, 14, 526-534.	2.0	118
190	Eastâ€"West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut, 2014, 63, 588-597.	12.1	321
191	eHealth. Inflammatory Bowel Diseases, 2014, 20, 2276-2285.	1.9	81
192	Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe. Inflammatory Bowel Diseases, 2014, 20, 36-46.	1.9	71
193	DOP067 Low FODMAP diet reduces irritable bowel symptoms and improves quality of life in patients with inflammatory bowel disease in a randomized controlled trial. Journal of Crohn's and Colitis, 2014, 8, S47.	1.3	2
194	Health-related quality of life improves during one year of medical and surgical treatment in a European population-based inception cohort of patients with Inflammatory Bowel Disease — An ECCO-EpiCom study ^{â⁻†} . Journal of Crohn's and Colitis, 2014, 8, 1030-1042.	1.3	59
195	OP008 The cost of investigations and medical treatment including biological therapy in a European inception cohort from the biological era – An ECCO-EpiCom study. Journal of Crohn's and Colitis, 2014, 8, S5-S6.	1.3	0
196	Environmental factors in a population-based inception cohort of inflammatory bowel disease patients in Europe â€" An ECCO-EpiCom study. Journal of Crohn's and Colitis, 2014, 8, 607-616.	1.3	81
197	Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: Results of the 2011 ECCO-EpiCom inception cohort. Journal of Crohn's and Colitis, 2014, 8, 1506-1515.	1.3	82
198	Age-related differences in presentation and course of inflammatory bowel disease: an update on the population-based literature. Journal of Crohn's and Colitis, 2014, 8, 1351-1361.	1.3	138

#	Article	IF	Citations
199	Health care and patients' education in a European inflammatory bowel disease inception cohort: An ECCO-EpiCom study. Journal of Crohn's and Colitis, 2014, 8, 811-818.	1.3	21
200	P474 Gut microbiota in patients with inflammatory bowel disease and irritable bowel syndrome before and after 6 weeks of low FODMAP diet. Journal of Crohn's and Colitis, 2014, 8, S264.	1.3	0
201	P293 eHealth: Individualisation of MMX mesalamine treatment and optimization of disease course via a self-managed web-based solution in active ulcerative colitis. Journal of Crohn's and Colitis, 2014, 8, S186.	1.3	0
202	Ehealth monitoring in irritable bowel syndrome patients treated with low fermentable oligo-, di-, mono-saccharides and polyols diet. World Journal of Gastroenterology, 2014, 20, 6680.	3.3	50
203	Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort. Danish Medical Journal, 2014, 61, B4778.	0.5	58
204	The burden of inflammatory bowel disease in Europe. Journal of Crohn's and Colitis, 2013, 7, 322-337.	1.3	781
205	Inflammatory bowel disease epidemiology. Current Opinion in Gastroenterology, 2013, 29, 357-362.	2.3	132
206	eHealth: individualisation of infliximab treatment and disease course via a selfâ€managed webâ€based solution in <scp>C</scp> rohn's disease. Alimentary Pharmacology and Therapeutics, 2012, 36, 840-849.	3.7	90
207	Mo1004 Is There an East-West Gradient in the Incidence of IBD in Europe? and Further Far East in China? First Results From the Epicom Study. Gastroenterology, 2012, 142, S-569-S-570.	1.3	1
208	Construction and validation of a web-based epidemiological database for inflammatory bowel diseases in Europe. Journal of Crohn's and Colitis, 2011, 5, 342-349.	1.3	30
209	Ehealth: Impact of Web-Based Treatment Optimization Solution (Traffic Light) on the Quality of Life in Crohn's Disease Patients Treated With Infliximab. Gastroenterology, 2011, 140, S-203-S-204.	1.3	4
210	A new rapid home test for faecal calprotectin in ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2010, 31, 323-330.	3.7	40
211	E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided â€~Constant-care' approach. Gut, 2010, 59, 1652-1661.	12.1	252
212	A new rapid home test for Faecal Calprotect in measurement by a mobile phone is reliable. Inflammatory Bowel Diseases, 2009, 15, S38.	1.9	0
213	Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment. European Journal of Gastroenterology and Hepatology, 2009, 22, 1.	1.6	51
214	Web based treatment solution: does learning in patient education center increase ulcerative colitis patient $\hat{\mathbb{E}}_{4}$ s knowlege level validated by Crohn Colitis knowledge score a DCCD study. Inflammatory Bowel Diseases, 2008, 14, S12.	1.9	0
215	Does level of information about Infliximab treatment to inflammatory bowel disease patients influence health quality of care? A DCCD, Danish Crohn Colitis Database Study. Inflammatory Bowel Diseases, 2008, 14, S21.	1.9	О
216	The impact of COVID-19 on patients with IBD in a prospective European cohort study. Journal of Crohn's and Colitis, 0 , , .	1.3	5